Seo Deok Hwa, Park Ji Woo, Jung Hee Won, Kang Min Woo, Kang Byung Yoon, Lee Dong Yeup, Lee Jae Jun, Yoon Seung Kew, Jang Jeong Won, Ahn Jae Gyoon, Sung Pil Soo
Department of Biomedicine and Health Sciences, The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Department of Computer Science and Engineering, Incheon National University, Incheon 22012, Republic of Korea.
Oncol Lett. 2024 Jul 15;28(3):438. doi: 10.3892/ol.2024.14571. eCollection 2024 Sep.
HCC (Hepatocellular carcinoma) is the most common malignant tumor; however, the molecular pathogenesis of these tumors is not well understood. Sorafenib, an approved treatment for HCC, inhibits angiogenesis and tumor cell proliferation. However, only ~30% of patients are sensitive to sorafenib and most show disease progression, indicating resistance to sorafenib. The present study used machine learning to investigate several mechanisms related to sorafenib resistance in liver cancer cells. This revealed that unphosphorylated interferon-stimulated genes (U-ISGs) were upregulated in sorafenib-resistant liver cancer cells, and the unphosphorylated ISGF3 (U-ISGF3; unphosphorylated STAT1, unphosphorylated STAT2 and IRF9) complex was increased in sorafenib-resistant liver cancer cells. Further study revealed that the knockdown of the U-ISGF3 complex downregulated U-ISGs. In addition, inhibition of the U-ISGF3 complex downregulated cell viability in sorafenib-resistant liver cancer cells. These results suggest that U-ISGF3 induced sorafenib resistance in liver cancer cells. Also, this mechanism may also be relevant to patients with sorafenib resistance.
肝细胞癌(HCC)是最常见的恶性肿瘤;然而,这些肿瘤的分子发病机制尚未完全明确。索拉非尼是一种已获批准用于治疗HCC的药物,可抑制血管生成和肿瘤细胞增殖。然而,只有约30%的患者对索拉非尼敏感,大多数患者病情进展,表明对索拉非尼耐药。本研究利用机器学习探究了肝癌细胞中与索拉非尼耐药相关的几种机制。结果显示,未磷酸化的干扰素刺激基因(U-ISGs)在索拉非尼耐药的肝癌细胞中上调,且未磷酸化的ISGF3(U-ISGF3;未磷酸化的STAT1、未磷酸化的STAT2和IRF9)复合物在索拉非尼耐药的肝癌细胞中增加。进一步研究表明,敲低U-ISGF3复合物可下调U-ISGs。此外,抑制U-ISGF3复合物可降低索拉非尼耐药肝癌细胞的细胞活力。这些结果表明,U-ISGF3诱导肝癌细胞产生索拉非尼耐药。而且,这种机制可能也与索拉非尼耐药患者有关。